Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials
10.1016/j.jhep.2020.06.025 · doi-reference
Challenges in the pharmaceutical development of lipid-based short interfering ribonucleic acid therapeutics
10.1517/17425247.2012.642363 · doi-reference
Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach
10.1038/s41575-023-00796-x · doi-reference
Anti-PEG antibodies: properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals
10.1016/j.addr.2020.07.024 · doi-reference
Considerations of the Japanese research working group for the ICH S6 & related issues regarding nonclinical safety assessments of oligonucleotide therapeutics: Comparison with those of biopharmaceuticals
10.1089/nat.2020.0879 · doi-reference
Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape
10.1038/nbt.2612 · doi-reference
Ligand-tethered lipid nanoparticles for targeted RNA delivery to treat liver fibrosis
10.1038/s41467-022-35637-z · doi-reference
pPB peptide-mediated siRNA-Loaded stable nucleic acid lipid nanoparticles on targeting therapy of hepatic fibrosis
10.1021/acs.molpharmaceut.7b00709 · doi-reference
Antioxidative hyaluronic acid–bilirubin nanomedicine targeting activated hepatic stellate cells for anti-hepatic-fibrosis therapy
10.1021/acsnano.3c06107 · doi-reference
Lipid nanoparticle-mediated hepatocyte delivery of siRNA and silibinin in metabolic dysfunction-associated steatotic liver disease
10.1016/j.jconrel.2024.07.011 · doi-reference
Liposomal drug delivery systems: from concept to clinical applications
10.1016/j.addr.2012.09.037 · doi-reference
Knocking down barriers: advances in siRNA delivery
10.1038/nrd2742 · doi-reference
Special delivery: targeted therapy with small RNAs
10.1038/gt.2011.56 · doi-reference
Rubicon siRNA-encapsulated liver-targeting nanoliposome is a promising therapeutic for non-alcoholic fatty liver disease
10.1016/j.ijpharm.2025.125291 · doi-reference
Evaluation of the therapeutic potential effect of Fas receptor gene knockdown in experimental model of non-alcoholic steatohepatitis
10.1080/10715762.2019.1608982 · doi-reference
Targeting a novel inducible GPX4 alternative isoform to alleviate ferroptosis and treat metabolic-associated fatty liver disease
10.1016/j.apsb.2022.02.003 · doi-reference
BMS-986263 in patients with advanced hepatic fibrosis: 36-week results from a randomized, placebo-controlled phase 2 trial
10.1002/hep.32181 · doi-reference
Phase I randomized double-blind study of an RNA interference therapeutic targeting HSD17B13 for metabolic dysfunction-associated steatohepatitis
10.1016/j.jhep.2025.05.031 · doi-reference
Preclinical and clinical pharmacokinetics of JNJ-75220795, an siRNA therapeutic targeting PNPLA3, for Metabolic dysfunction-associated steatohepatitis
10.1002/jcph.6174 · doi-reference
Plozasiran (ARO-APOC3) for severe hypertriglyceridemia: the SHASTA-2 randomized clinical trial
10.1001/jamacardio.2024.0959 · doi-reference
CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis
10.1056/nejmoa2107454 · doi-reference
Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours
10.1038/s41416-020-0802-1 · doi-reference
AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: two randomized phase I trials
10.1016/j.jhep.2024.12.046 · doi-reference
Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA
10.1038/nbt1081 · doi-reference
Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity
10.1038/s41467-018-02989-4 · doi-reference
Nucleoside modifications in RNA limit activation of 2'-5'-oligoadenylate synthetase and increase resistance to cleavage by RNase L
10.1093/nar/gkr586 · doi-reference
RNAi-based drug design: considerations and future directions
10.1038/s41573-024-00912-9 · doi-reference
RNA interference in the clinic: challenges and future directions
10.1038/nrc2966 · doi-reference
RNAi therapeutic and its innovative biotechnological evolution
10.1016/j.biotechadv.2019.04.012 · doi-reference
Phase 1 trials of PNPLA3 siRNA in I148M Homozygous Patients with MAFLD
10.1056/nejmc2402341 · doi-reference
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials
10.1016/j.jhep.2020.02.027 · doi-reference
Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by Nonalcoholic steatohepatitis
10.1053/j.gastro.2018.07.006 · doi-reference
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
10.1016/s0140-6736(19)33041-7 · doi-reference
FXR agonists for MASH therapy: lessons and perspectives from obeticholic acid
10.1002/med.21991 · doi-reference
Obeticholic acid impact on quality of life in patients with nonalcoholic steatohepatitis: REGENERATE 18-Month interim analysis
10.1016/j.cgh.2021.07.020 · doi-reference
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
10.1016/s0140-6736(14)61933-4 · doi-reference
Long-term pioglitazone treatment for patients with Nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial
10.7326/m15-1774 · doi-reference
Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors
10.1038/s41575-020-00366-5 · doi-reference
Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD)
10.1016/j.phrs.2023.106786 · doi-reference
Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis
10.1056/nejmoa2413258 · doi-reference
